


Respiratory Pathogens Data Jun 29 - Oct 6 2018

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Mycoplasma	Chlamydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
SEP 28	0	0	0	0	1	10	103	2	1	2	2	3	0	124	0	410	0.0	n/a	n/a	1.7
SEP 21	0	0	0	0	1	10	107	1	6	3	3	0	2	133	0	388	0.0	0.8	0.9	0.9
SEP 14	0	0	0	0	2	9	135	0	2	0	5	1	0	154	0	415	0.0	0.7	1.0	0.7
SEP 7	0	0	0	0	0	9	113	0	4	0	1	1	0	128	0	370	0.0	1.7	0.5	0.9
AUG 31	0	0	1	0	1	6	84	1	3	1	5	0	0	102	1	338	0.8	1.8	0.7	0.7
AUG 24	0	1	0	0	1	3	67	1	0	0	2	0	0	75	1	258	0.0	1.6	0.2	6.9
AUG 17	0	0	0	0	0	8	42	1	1	2	1	0	1	56	0	267	0.0	0.3	1.2	2.3
AUG 10	0	0	2	0	0	6	55	2	2	1	1	1	0	70	2	246	0.8	0.9	0.2	3.4
AUG 3	0	0	0	0	0	5	35	1	5	0	0	0	0	46	0	229	0.0	1.0	0.2	0.0
JULY 27	0	0	0	0	0	12	44	1	8	1	2	1	1	70	0	288	0.0	1.0	0.2	0.0
JULY 20	0	0	0	0	1	32	43	1	3	0	1	1	0	82	0	304	0.0	0.6	0.9	0.0
JULY 13	0	0	0	0	0	27	42	0	5	1	1	0	1	77	0	274	0.0	1.0	0.6	0.0
JULY 6	0	0	0	0	2	29	56	3	1	2	2	1	1	97	0	284	0.0	1.0	0.2	1.6
JUNE 29	0	1	0	0	0	33	67	0	1	1	1	0	0	104	1	295	0.0	1.1	0.4	0.0


ACL RESP. PANEL - POSITIVITY RATE All 2018 - 30.2%

- All Corona
- Chla mydia
- Myco plasma
- All Para
- Adeno
- Meta pneumo
- EV / Rhino
- RSV
- Inf B
- InfA-H3
- 2009 H1N1
- InfA-H1
- Bocca




ACL Influenza PCR POS 0 %

◆ POS FLU
■ Total



ACL FLUAG EIA POS 1.7 %

■ Total
▲ POS EIA




CDC Sep 29, 2018 **Positivity rate 0.8%** - Flu A – 68% , Flu B – 32%




Influenza Positive Tests Reported to CDC by Clinical Laboratories, National Summary,
2017-18 Season, week ending Sep 29, 2018

Reported by: U.S. WHO/NREVSS Collaborating Laboratories and ILINet




Check All Percent Positive Percent Positive for Influenza A Percent Positive for Influenza B Total A Total B


The most prevalent target as **Sep 29^t** were **EV, PEV** (overall CSF positivity rate is **21.5%**)




The most prevalent targets as Sep 29 were Giardia and Campy



The most prevalent target as Sep 29th was Adeno



	BV-Bacterial vaginosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	22.1	13.2	2.2	0.4	3.1	0.1	7.1	19.8	48.2



Neuraminidase Inhibitors Resistance in Samples Collected - Oct 1- May 20, 2018,

No updates from CDC during summer months

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	1124	11(1.0)	763	0	1124	11(1.0)
Influenza A (H3N2)	2347	0	2347	0	1241	0
Influenza B	1087	0	1087	0	1087	0